<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230715085802&amp;utm_campaign=pubmed-2&amp;utm_source= Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230715085802&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 15 日星期六 12:58:04 +0000</lastbuilddate><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>素食和纯素饮食：优点和缺点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37450568/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>植物性饮食因其所谓的健康益处以及最近对环境的积极影响而变得越来越受欢迎。前瞻性研究表明，食用素食可降低患心血管疾病 (CVD)、糖尿病、高血压、痴呆症的风险，随机临床试验的数据已证实素食对于预防糖尿病以及减轻体重、血压等具有保护作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad436.doi: 10.1093/eurheartj/ehad436. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">植物性饮食因其所谓的健康益处以及最近对环境的积极影响而变得越来越受欢迎。前瞻性研究表明，食用素食可降低患心血管疾病 (CVD)、糖尿病、高血压、痴呆症的风险，随机临床试验的数据已证实素食对预防糖尿病以及降低体重、血压、糖化血红蛋白和低密度脂蛋白胆固醇具有保护作用，但迄今为止，还没有心血管事件发生率的数据。所有植物性食品都同样健康。不健康的素食饮食缺乏特定营养素（维生素 B12、铁、锌和钙）和/或富含高度加工的食品。需要进一步的机制研究来了解健康的、最低限度加工的素食是否具有优势饮食代表了一种全有或全无的现象，以及主要食用含有少量动物产品的植物性饮食（例如pesco素食或地中海饮食）是否对心脏代谢健康结果有有益、有害或中性影响。此外，机制研究是有必要增强我们对健康植物性食物模式以及与饮食因素、CVD 和其他代谢疾病相关的生物学机制的理解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37450568/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37450568</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad436>10.1093/eurheartj/ehad436</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37450568</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>王田</dc:creator><dc:creator>安德鲁斯·马塞敦斯卡斯</dc:creator><dc:creator>沃尔特·威利特</dc:creator><dc:creator>路易吉丰塔纳</dc:creator><dc:date>2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>素食和纯素饮食：优点和缺点</dc:title><dc:identifier>下午：37450568</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad436</dc:identifier></item><item><title> 《欧洲心脏杂志》的主要贡献机构：英国皇家布朗普顿医院和哈尔菲尔德医院</title><link/>https://pubmed.ncbi.nlm.nih.gov/37450561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad442.doi: 10.1093/eurheartj/ehad442. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37450561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37450561</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad442>10.1093/eurheartj/ehad442</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37450561</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>《欧洲心脏杂志》的主要贡献机构：英国皇家布朗普顿医院和哈尔菲尔德医院</dc:title><dc:identifier>下午：37450561</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad442</dc:identifier></item><item><title>心房颤动相关基因 &lt;em>;Zfhx3&lt;/em>; 的丢失会导致心房扩张和心律失常</title><link/>https://pubmed.ncbi.nlm.nih.gov/37449401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>结论：我们的研究结果表明 ZFHX3 是 16q22 位点上 AF 的致病基因，心脏 Zfhx3 缺失引起的心脏异常是由于参与 AF 易感性的心房特异性通路失调所致。总而言之，这些数据揭示了一种新颖且重要的作用Zfhx3 控制正常心房功能所必需的心脏基因和信号通路。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 14 日。doi：10.1161/CIRCRESAHA.123.323029。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景： <i>ZFHX3</i>是一种编码大转录因子的基因，是与心房颤动（AF）第二显着相关的位点，但其在心脏中的功能尚不清楚。本研究旨在确定与 AF 相关的致病遗传变异。 <i>ZFHX3</i>基因座并检查<i>Zfhx3</i>缺失对小鼠心脏功能的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在多能干细胞衍生的心肌细胞中使用 CRISPR-Cas9 基因组编辑、染色质免疫沉淀和荧光素酶测定来识别<i>ZFHX3</i>位点与 AF 相关的致病遗传变异。通过超声心动图、磁共振成像、电生理学研究、对杂合子和纯合子心肌细胞限制性<i>Zfhx3</i>缺失（分别为<i>Zfhx3</i> Het 和敲除）小鼠进行钙成像和 RNA 测序。分析人心脏单核 ATAC 测序数据，以确定心房心肌细胞中的哪些基因直接受<i>ZFHX3</i>调节。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现 SNP rs12931021 调节<i>ZFHX3</i>表达的增强子，并且 AF 风险等位基因与<i>ZFHX3</i>转录减少相关。我们观察到 Zfhx3 敲除小鼠的 AF 易感性基因剂量反应，其 AF 发生率、频率和负担高于<i>Zfhx3</i> Het 和野生型小鼠，传导速度、心房动作电位持续时间、钙处理以及心房扩大和血栓以及扩张型心肌病的发生发生变化<i>。Zfhx3</i>缺失导致心房特异性差异效应，涉及相关基因和信号通路心脏病理生理学和 AF。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究结果表明<i>ZFHX3</i>是 16q22 位点上 AF 的致病基因，心脏<i>Zfhx3</i>缺失引起的心脏异常是由于参与 AF 易感性的心房特异性通路失调所致。总而言之，这些数据揭示了一种新颖且重要的作用<i>Zfhx3</i>控制正常心房功能所必需的心脏基因和信号通路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37449401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37449401</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323029>10.1161/CIRCRESAHA.123.323029</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37449401</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>希瑟·詹姆森</dc:creator><dc:creator>——艾伦·汉利</dc:creator><dc:creator>——马修·C·希尔</dc:creator><dc:creator>凌霄</dc:creator><dc:creator>叶江川</dc:creator><dc:creator>阿尼什·巴帕特</dc:creator><dc:creator>埃尔莎·罗齐尔</dc:creator><dc:creator>阿米莉亚·韦伯·霍尔</dc:creator><dc:creator>——威廉·J·哈克</dc:creator><dc:creator>塞巴斯蒂安·克劳斯</dc:creator><dc:creator>米兰达·巴拉扎</dc:creator><dc:creator>伊丽莎白·西尔伯</dc:creator><dc:creator>朱莉·米娜</dc:creator><dc:creator>——内森·R·塔克</dc:creator><dc:creator>——罗伯特·W·米尔斯</dc:creator><dc:creator>董金堂</dc:creator><dc:creator>大卫·J·米兰</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:date>2023-07-14</dc:date><dc:source>流通研究</dc:source><dc:title>心房颤动相关基因 &lt;em>;Zfhx3&lt;/em>; 的丢失会导致心房扩张和心律失常</dc:title><dc:identifier>下午：37449401</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323029</dc:identifier></item><item><title>消除动脉粥样硬化性心血管疾病的残余风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37448228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad446.doi: 10.1093/eurheartj/ehad446. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37448228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37448228</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad446>10.1093/eurheartj/ehad446</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37448228</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——迈克尔·E·马科弗</dc:creator><dc:creator>斯坦尼斯瓦夫·苏尔马</dc:creator><dc:creator>马切伊·巴纳赫</dc:creator><dc:creator>彼得·P·托特</dc:creator><dc:date>2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>消除动脉粥样硬化性心血管疾病的残余风险</dc:title><dc:identifier>下午：37448228</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad446</dc:identifier></item><item><title>心脏代谢风险管理：欧洲心脏病学会心血管圆桌会议的见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37448181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>代谢合并症在心肾疾病患者中很常见；它们可导致动脉粥样硬化性心血管疾病 (ASCVD)，加速病情进展并对预后产生不利影响。常见合并症包括 2 型糖尿病 (T2DM)、肥胖/超重、慢性肾脏病 (CKD)、心血管系统、肾脏和肝脏与许多相同的危险因素有关（例如血脂异常、高血压、吸烟、糖尿病和中央/躯干肥胖），... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 14:ehad445.doi: 10.1093/eurheartj/ehad445. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">代谢合并症在心肾疾病患者中很常见；它们可导致动脉粥样硬化性心血管疾病 (ASCVD)，加速病情进展并对预后产生不利影响。常见合并症包括 2 型糖尿病 (T2DM)、肥胖/超重、慢性肾脏病 (CKD)、心血管系统、肾脏和肝脏与许多相同的危险因素有关（例如血脂异常、高血压、吸烟、糖尿病和中央/躯干肥胖），并且共同的代谢和功能异常会导致全身损害。这些器官通过重叠病理生理学途径。COVID-19 大流行使心脏代谢疾病的管理进一步复杂化。肥胖、T2DM、CKD 和肝病与 COVID-19 感染不良结局的风险增加相关，相反，COVID-19 可能导致病情恶化这些合并症的高发生率凸显了需要提高肥胖、胰岛素抵抗或 T2DM、慢性肝病和 CKD 患者对 ASCVD 的认识和治疗，同样，需要提高对这些疾病的认识和治疗ASCVD 患者。预防和管理心脏代谢疾病的策略包括生活方式改变、药物治疗和手术。社会层面需要更多的计划来鼓励健康饮食和身体活动。可以针对跨疾病的多种病理生理途径的方法。非手术和手术减肥策略可以改善肥胖症患者的心脏代谢紊乱。正在研究的新生物标志物可能有助于早期识别处于危险中的个体并揭示新的治疗目标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37448181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37448181</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad445>10.1093/eurheartj/ehad445</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37448181</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>弗朗西斯科·科森蒂诺</dc:creator><dc:creator>Subodh Verma更多</dc:creator><dc:creator>菲利普·安伯里</dc:creator><dc:creator>玛丽安·巴赫·特雷彭达尔</dc:creator><dc:creator>马丁·范·艾克斯</dc:creator><dc:creator>斯特凡·D·安克</dc:creator><dc:creator>米歇尔·切基尼</dc:creator><dc:creator>保拉·菲奥雷托</dc:creator><dc:creator>佩尔·亨里克·格鲁普</dc:creator><dc:creator>大卫·赫斯</dc:creator><dc:creator>卡姆莱什·昆提</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>伊莎贝尔·理查德·洛德罗</dc:creator><dc:creator>拉尔斯·H·隆德</dc:creator><dc:creator>保罗·麦克格里维</dc:creator><dc:creator>菲利普·纽瑟姆</dc:creator><dc:creator>纳维德·萨塔尔</dc:creator><dc:creator>斯科特·所罗门</dc:creator><dc:creator>弗朗茨·魏丁格</dc:creator><dc:creator>Faiez Zannad更多</dc:creator><dc:creator>安德烈亚斯·泽赫</dc:creator><dc:date>2023-07-14</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心脏代谢风险管理：欧洲心脏病学会心血管圆桌会议的见解</dc:title><dc:identifier>下午：37448181</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad445</dc:identifier></item><item><title> FGF23 和 klotho 处于肾脏和心血管疾病的交叉点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37443358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>心血管疾病是慢性肾病 (CKD) 患者死亡的主要原因。随着 CKD 的进展，CKD 特有的危险因素（例如矿物质稳态紊乱）会放大传统的心血管危险因素。成纤维细胞生长因子 23 (FGF23) 调节矿物质稳态通过激活 FGF 受体和跨膜 klotho 辅助受体的复合物。可溶形式的 klotho 还在不表达 klotho 的组织中充当“便携式”FGF23 辅助受体。在... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 7 月 13 日。doi：10.1038/s41569-023-00903-0。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心血管疾病是慢性肾病 (CKD) 患者死亡的主要原因。随着 CKD 的进展，CKD 特有的危险因素（例如矿物质稳态紊乱）会放大传统的心血管危险因素。成纤维细胞生长因子 23 (FGF23) 调节矿物质稳态通过激活 FGF 受体和跨膜 klotho 辅助受体的复合物。klotho 的可溶形式也可在不表达 klotho 的组织中充当“便携式”FGF23 辅助受体。在进行性 CKD 中，循环 FGF23 水平升高与肾功能下降相结合klotho 的表达导致 FGF23 对心脏产生独立于 klotho 的影响，从而促进左心室肥大、心力衰竭、心房颤动和死亡。新出现的数据表明，可溶性 klotho 可能通过几种候选机制减轻其中一些影响。需要更多的研究来证实研究 CKD 特定心血管并发症中的 FGF23 过量和 klotho 缺乏，但考虑到 FGF23 过量与 klotho 缺乏共同的纠缠反馈环路，FGF23 过量与 klotho 缺乏的病理生理学首要地位可能永远不会得到精确解决。因此，随机试验应优先考虑临床实用性而不是科学确定性：全面针对矿物质稳态紊乱，努力改善 CKD 患者的心血管结局。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37443358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37443358</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00903-0>10.1038/s41569-023-00903-0</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37443358</guid><pubDate> Fri, 14 Jul 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·埃德蒙斯顿</dc:creator><dc:creator>亚历山大·格拉布纳</dc:creator><dc:creator>迈尔斯·沃尔夫</dc:creator><dc:date>2023-07-14</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>FGF23 和 klotho 处于肾脏和心血管疾病的交叉点</dc:title><dc:identifier>下午：37443358</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00903-0</dc:identifier></item><item><title>应对心房颤动的流行：优化导管消融和新的治疗靶点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37442559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 《欧洲心脏杂志》2023 年 7 月 14 日；44(27):2413-2416.doi: 10.1093/eurheartj/ehad438。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37442559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37442559</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad438>10.1093/eurheartj/ehad438</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37442559</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-07-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>应对心房颤动的流行：优化导管消融和新的治疗靶点</dc:title><dc:identifier>下午：37442559</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad438</dc:identifier></item><item><title>单细胞空间转录组揭示了猕猴皮层的细胞类型组织</title><link/>https://pubmed.ncbi.nlm.nih.gov/37442136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>通过对 143 个猕猴皮层区域进行大规模单核 RNA 测序和空间转录组分析，我们获得了 264 个转录组定义的皮层细胞类型的综合图谱，并描述了皮层层和谷氨酸能、GABA 能和非神经元的区域偏好细胞... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 7 日：S0092-8674(23)00679-7.doi: 10.1016/j.cell.2023.06.009.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">通过对 143 个猕猴皮质区域进行大规模单核 RNA 测序和空间转录组分析，我们获得了 264 种转录组定义的皮质细胞类型的综合图谱，并绘制了它们在整个皮质中的空间分布。我们表征了皮质层和区域偏好谷氨酸能、GABA能和非神经元细胞类型，以及细胞类型组成和邻域复杂性的区域差异，各种细胞类型的区域分布以及视觉和体感系统中区域的层次水平。来自人类、猕猴和小鼠皮质的转录组数据进一步揭示了在第 4 层富集的灵长类特异性细胞类型，其标记基因以区域依赖性方式表达。我们的数据为理解进化、发育提供了细胞和分子基础、灵长类大脑的衰老和发病机制。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37442136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37442136</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.009>10.1016/j.cell.2023.06.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37442136</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>陈傲</dc:creator><dc:creator>孙一迪</dc:creator><dc:creator>英蕾</dc:creator><dc:creator>李超</dc:creator><dc:creator>杀了更多</dc:creator><dc:creator>孟娟</dc:creator><dc:creator>白益勤</dc:creator><dc:creator>刘震</dc:creator><dc:creator>梁志峰</dc:creator><dc:creator>朱志勇</dc:creator><dc:creator>妮妮园</dc:creator><dc:creator>浩阳</dc:creator><dc:creator>吴子涵</dc:creator><dc:creator>林峰</dc:creator><dc:creator>王可欣</dc:creator><dc:creator>梅莉</dc:creator><dc:creator>张淑珍</dc:creator><dc:creator>杨梅松</dc:creator><dc:creator>费天一</dc:creator><dc:creator>庄振坤</dc:creator><dc:creator>黄一鸣</dc:creator><dc:creator>张勇</dc:creator><dc:creator>徐元芳</dc:creator><dc:creator>崔鲁曼更多</dc:creator><dc:creator>张瑞怡</dc:creator><dc:creator>韩雷</dc:creator><dc:creator>孙兴</dc:creator><dc:creator>陈碧超</dc:creator><dc:creator>李文娇</dc:creator><dc:creator>皇甫宝前</dc:creator><dc:creator>马凯龙</dc:creator><dc:creator>马建云</dc:creator><dc:creator>赵莉</dc:creator><dc:creator>林毅坤</dc:creator><dc:creator>何王</dc:creator><dc:creator>钟延庆</dc:creator><dc:creator>张慧芳</dc:creator><dc:creator>钱宇</dc:creator><dc:creator>王亚谦</dc:creator><dc:creator>刘星</dc:creator><dc:creator>彭健</dc:creator><dc:creator>刘传玉</dc:creator><dc:creator>陈伟</dc:creator><dc:creator>潘文涛</dc:creator><dc:creator>安英杰</dc:creator><dc:creator>夏世惠</dc:creator><dc:creator>盐兵路</dc:creator><dc:creator>王明丽</dc:creator><dc:creator>宋新祥</dc:creator><dc:creator>刘帅</dc:creator><dc:creator>王志峰</dc:creator><dc:creator>春宫</dc:creator><dc:creator>黄鑫</dc:creator><dc:creator>悦源</dc:creator><dc:creator>赵云</dc:creator><dc:creator>柴勤文</dc:creator><dc:creator>杏坛</dc:creator><dc:creator>刘剑锋</dc:creator><dc:creator>郑明远</dc:creator><dc:creator>李胜康</dc:creator><dc:creator>黄雅玲</dc:creator><dc:creator>颜红</dc:creator><dc:creator>黄自瑞</dc:creator><dc:creator>李敏</dc:creator><dc:creator>金萌萌</dc:creator><dc:creator>李艳</dc:creator><dc:creator>张慧</dc:creator><dc:creator>孙苏红</dc:creator><dc:creator>李高</dc:creator><dc:creator>白银其</dc:creator><dc:creator>蒙南成</dc:creator><dc:creator>胡国海</dc:creator><dc:creator>刘航运</dc:creator><dc:creator>王博</dc:creator><dc:creator>宾翔</dc:creator><dc:creator>李淑婷</dc:creator><dc:creator>李欢欢</dc:creator><dc:creator>陈梦妮</dc:creator><dc:creator>王世文</dc:creator><dc:creator>李明龙</dc:creator><dc:creator>刘伟斌</dc:creator><dc:creator>刘鑫</dc:creator><dc:creator>赵谦</dc:creator><dc:creator>迈克尔·利斯比</dc:creator><dc:creator>王静</dc:creator><dc:creator>焦芳</dc:creator><dc:creator>云林</dc:creator><dc:creator>谢清更多</dc:creator><dc:creator>刘震</dc:creator><dc:creator>何杰</dc:creator><dc:creator>徐华泰</dc:creator><dc:creator>黄伟</dc:creator><dc:creator>简·穆德</dc:creator><dc:creator>杨焕明</dc:creator><dc:creator>孙彦刚</dc:creator><dc:creator>马蒂亚斯·乌伦</dc:creator><dc:creator>蒲慕明</dc:creator><dc:creator>王健</dc:creator><dc:creator>姚建华</dc:creator><dc:creator>吴伟</dc:creator><dc:creator>李玉祥</dc:creator><dc:creator>沉志明</dc:creator><dc:creator>刘龙琪</dc:creator><dc:creator>刘志勇</dc:creator><dc:creator>徐迅</dc:creator><dc:creator>李成玉</dc:creator><dc:date>2023-07-13</dc:date><dc:source>细胞</dc:source><dc:title>单细胞空间转录组揭示了猕猴皮层的细胞类型组织</dc:title><dc:identifier>下午：37442136</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.009</dc:identifier></item><item><title>严重感染抗血栓治疗患者的管理：ESC血栓形成工作组、ESC动脉粥样硬化和血管生物学工作组以及国际血栓和止血学会联合临床共识声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>患有严重感染且已有抗血栓治疗指征（即抗血小板药物、抗凝药物或其组合）的患者需要凝血、感染性疾病和心脏病专家之间的综合临床咨询，因为脓毒症引起的凝血病经常发生。病毒病原体对全球公共卫生构成越来越大的威胁，特别是对于正在接受抗血栓治疗的患者来说，这些患者有很高的风险…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 13:ehad388.doi: 10.1093/eurheartj/ehad388. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">患有严重感染且已有抗血栓治疗指征（即抗血小板药物、抗凝药物或其组合）的患者需要凝血、感染性疾病和心脏病专家之间的综合临床咨询，因为脓毒症引起的凝血病经常发生。病毒病原体对全球公共卫生构成越来越大的威胁，特别是对于正在进行抗血栓治疗的患者来说，他们血栓复发的风险很高，并且对严重感染的易感性很高，从而导致发病率和死亡率增加。凝血功能障碍常常使严重感染复杂化，与死亡率高，临床医生有义务调整抗血栓药物类型和剂量，以避免出血，同时预防血栓并发症。本临床共识声明回顾了现有的最佳证据，为因严重细菌或病毒感染而住院的患者的治疗提供专家意见和声明-抗血栓治疗（单一或联合）的现有适应症，其中经常观察到脓毒症引起的凝血病。平衡这些患者的血栓形成和出血风险并使用疫苗预防感染（如果有）对于预防事件或改善结果至关重要；预后。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37439553</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad388>10.1093/eurheartj/ehad388</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439553</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>布鲁纳·吉甘特</dc:creator><dc:creator>杰罗德·H·利维</dc:creator><dc:creator>埃里克·范·戈尔普</dc:creator><dc:creator>亚历山德罗·巴托洛尼</dc:creator><dc:creator>玛丽·露丝·博查顿·皮亚拉</dc:creator><dc:creator>马格努斯·贝克</dc:creator><dc:creator>雨果十大美食</dc:creator><dc:creator>克里斯蒂娜·克里斯特森</dc:creator><dc:creator>何塞·路易斯·费雷罗</dc:creator><dc:creator>托比亚斯·盖斯勒</dc:creator><dc:creator>埃丝特·鲁特根斯</dc:creator><dc:creator>——萨姆·舒尔曼</dc:creator><dc:creator>罗伯特·F·斯托里</dc:creator><dc:creator>杰科·塔奇尔</dc:creator><dc:creator>杰玛·维拉胡尔</dc:creator><dc:creator>Patricia C Liaw更多</dc:creator><dc:creator>比安卡·罗卡</dc:creator><dc:date>2023-07-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>严重感染抗血栓治疗患者的管理：ESC血栓形成工作组、ESC动脉粥样硬化和血管生物学工作组以及国际血栓和止血学会联合临床共识声明</dc:title><dc:identifier>下午：37439553</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad388</dc:identifier></item><item><title> BNT162b2 和 mRNA-1273 疫苗接种对健康成人血管功能的影响：初步研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 13 日。doi：10.1161/CIRCRESAHA.122.322862。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37439257</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.322862>10.1161/CIRCRESAHA.122.322862</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439257</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>科琳娜·塞文特</dc:creator><dc:creator>亚历克斯·马蒂亚斯</dc:creator><dc:creator>米娅·卡尔德隆</dc:creator><dc:creator>穆罕默德·埃内斯·埃罗尔</dc:creator><dc:creator>斯图尔特·奇普金</dc:creator><dc:creator>格温纳尔·拉耶克</dc:creator><dc:date>2023-07-13</dc:date><dc:source>流通研究</dc:source><dc:title>BNT162b2 和 mRNA-1273 疫苗接种对健康成人血管功能的影响：初步研究</dc:title><dc:identifier>下午：37439257</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322862</dc:identifier></item><item><title>双器官移植：心肾和心肝移植的适应症、评估和结果：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>虽然心脏移植是晚期心力衰竭患者的首选治疗方法，但同时存在的肾或肝功能障碍可能会对孤立心脏移植构成障碍。因此，对同步心肾移植和同步心肝移植有明确的指导是迫切需要的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 13 日。doi：10.1161/CIR.0000000000001155。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">虽然心脏移植是晚期心力衰竭患者的首选治疗方法，但同时存在的肾或肝功能障碍可能会对孤立心脏移植构成障碍。因此，对同步心肾移植和同步心肝移植有明确的指导迫切需要（3）为同时心肾移植和同时心肝移植的患者选择和移植后管理提供方法；（4）探索多器官移植的伦理学。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37439224</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001155>10.1161/CIR.0000000000001155</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439224</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——米歇尔·M·基特尔森</dc:creator><dc:creator>卡维塔·夏尔马</dc:creator><dc:creator>丹尼尔·布伦南</dc:creator><dc:creator>程星星</dc:creator><dc:creator>周雪儿</dc:creator><dc:creator>莫妮卡·科尔文</dc:creator><dc:creator>——亚当·D·德沃尔</dc:creator><dc:creator>香农·M·邓利</dc:creator><dc:creator>——梅格·弗雷泽</dc:creator><dc:creator>杰奎琳·加隆齐克·王</dc:creator><dc:creator>普拉泰提·哈赞尼</dc:creator><dc:creator>——凯文·M·科伦布拉特</dc:creator><dc:creator>范德T</dc:creator><dc:creator>美国心脏协会临床心脏病学委员会心力衰竭和移植委员会；心血管疾病肾脏委员会；心血管手术和麻醉委员会；心血管和中风护理委员会；先天性心脏病和年轻人心脏健康</dc:creator><dc:date>2023-07-13</dc:date><dc:source>循环</dc:source><dc:title>双器官移植：心肾和心肝移植的适应症、评估和结果：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37439224</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001155</dc:identifier></item><item><title> STREAM-2 中半剂量替奈普酶或初次经皮冠状动脉介入治疗老年 ST 段抬高型心肌梗死患者：一项随机、开放标签试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37439219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>结论：在这种早期出现的老年 STEMI 人群中，在药物侵入策略中将替奈普酶剂量减半与心电图变化相关，这些变化至少与直接 PCI 后的变化相当。两个治疗组中出现相似的临床疗效和血管造影终点半剂量替奈普酶的颅内出血风险高于直接 PCI。如果无法及时进行 PCI，这种药物侵入策略是一种合理的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 13 日。doi：10.1161/CIRCULATIONAHA.123.064521。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：ST 段抬高型心肌梗死 (STEMI) 指南建议，如果无法及时进行直接经皮冠状动脉介入治疗 (PCI)，则建议采用药物侵入性治疗。全剂量替奈普酶会增加老年患者颅内出血的风险。半剂量替奈普酶对于老年 STEMI 患者是否有效且安全尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：STREAM-2（心肌梗死后早期老年患者的策略性再灌注）是一项研究者发起的、开放标签、随机、多中心研究。患者年龄≥60岁，2个连续导联ST段抬高≥2mm，无法在 1 小时内接受直接 PCI 的患者，被随机分配 (2:1) 接受半剂量替奈普酶治疗，然后在随机分组后 6 至 24 小时进行冠状动脉造影和 PCI（如果需要），或接受直接 PCI。 主要关注的疗效终点是 ST 消退和 30 天的死亡、休克、心力衰竭或再梗塞综合情况。安全性评估包括中风和非颅内出血。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者被分配接受药物侵入性治疗 (n=401) 或直接 PCI (n=203)。从随机分组到替奈普酶或鞘管插入的中位时间分别为 10 分钟和 81 分钟。最后一次血管造影后，85.2% 的患者接受了药物侵入性治疗和 78.4% 接受直接 PCI 的患者 ST 段抬高的缓解率≥50%；他们的 ST 段偏差的残余中位总和分别为 4.5 毫米和 5.5 毫米。最后一次血管造影时心肌梗塞血流 3 级溶栓治疗为 ≈两组均为 87%。复合临床终点发生在接受药物侵入性治疗的患者中为 12.8% (51/400)，在接受直接 PCI 的患者中为 13.3% (27/203)（相对风险，0.96 [95% CI， 0.62-1.48]）。药物侵入组发生 6 例颅内出血（1.5%）：3 例违反方案（2 例过度抗凝，1 例高血压未控制）。初次 PCI 组未发生颅内出血。主要非颅内出血两组的比例均较低（&lt;1.5%）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在这种早期出现的老年 STEMI 人群中，在药物侵入策略中将替奈普酶剂量减半与心电图变化相关，这些变化至少与直接 PCI 后的变化相当。两个治疗组中出现相似的临床疗效和血管造影终点半剂量替奈普酶的颅内出血风险高于直接PCI。如果无法及时进行PCI，这种药物侵入性策略是一个合理的替代方案，前提是观察到纤溶禁忌症并避免过度抗凝。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT02777580。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37439219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37439219</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064521>10.1161/CIRCULATIONAHA.123.064521</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37439219</guid><pubDate> Thu, 13 Jul 2023 06:00:00 -0400</pubDate><dc:creator>弗兰斯·范德沃夫</dc:creator><dc:creator>阿森·D·里斯蒂奇</dc:creator><dc:creator>奥列格·V·阿维尔科夫</dc:creator><dc:creator>亚历山德拉·阿里亚斯·门多萨</dc:creator><dc:creator>伊夫·兰伯特</dc:creator><dc:creator>何塞·F·科尔·萨莱瓦</dc:creator><dc:creator>巴勃罗·塞普尔韦达</dc:creator><dc:creator>费尔南多·罗塞尔-奥尔蒂斯</dc:creator><dc:creator>约翰·K·弗伦奇</dc:creator><dc:creator>Ljilja B 音乐</dc:creator><dc:creator>凯琳·范登伯格</dc:creator><dc:creator>克里斯·博加茨</dc:creator><dc:creator>辛西娅·M·韦斯特豪特</dc:creator><dc:creator>阿兰·佩吉斯</dc:creator><dc:creator>蒂埃里·达内斯</dc:creator><dc:creator>——凯文·R·贝尼</dc:creator><dc:creator>彼得·辛尼夫</dc:creator><dc:creator>——帕特里克·戈德斯坦</dc:creator><dc:creator>——罗伯特·C·威尔士</dc:creator><dc:creator>保罗·W·阿姆斯特朗</dc:creator><dc:creator>STREAM-2 调查员</dc:creator><dc:date>2023-07-13</dc:date><dc:source>循环</dc:source><dc:title>STREAM-2 中半剂量替奈普酶或初次经皮冠状动脉介入治疗老年 ST 段抬高型心肌梗死患者：一项随机、开放标签试验</dc:title><dc:identifier>下午：37439219</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064521</dc:identifier></item><item><title>生命早期累积的危险因素暴露</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):e19.doi: 10.1016/j.jacc.2023.04.055。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438013</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.055>10.1016/j.jacc.2023.04.055</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438013</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>拉姆达斯·G·派</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>生命早期累积的危险因素暴露</dc:title><dc:identifier>下午：37438013</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.055</dc:identifier></item><item><title>肥厚型心肌病合并心房颤动患者发生左心房血栓的风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 18 日；82(3):278-279.doi:10.1016/j.jacc.2023.05.021。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37438012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438012</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.021>10.1016/j.jacc.2023.05.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37438012</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——丹尼尔·R·布尔扎克</dc:creator><dc:creator>Raghav R Julakanti更多</dc:creator><dc:creator>阿卜杜拉·卡拉·巴拉</dc:creator><dc:creator>克里斯托弗·斯科特</dc:creator><dc:creator>杰弗里·B·盖斯克</dc:creator><dc:creator>史蒂夫·R·奥曼</dc:creator><dc:creator>乌伊西勒·T·恩科莫</dc:creator><dc:creator>——伯纳德·J·格什</dc:creator><dc:creator>彼得·鼻子</dc:creator><dc:creator>康斯坦丁诺斯·西昂蒂斯</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>肥厚型心肌病合并心房颤动患者发生左心房血栓的风险</dc:title><dc:identifier>下午：37438012</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.021</dc:identifier></item><item><title>避免接受血管内主动脉弓修复术的患者发生中风：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37438011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230715085802&amp;v=2.17.9.post6+86293ac<description> As the bottleneck of endovascular aortic arch repair, early postoperative stroke remains a devastating complication in high-risk patients and a critical concern for the development of optimal endovascular techniques and devices. The incidence of early postoperative stroke varies widely among currently available endovascular techniques and devices, with reported rates ranging from 0.0% to 42.9%, and is significantly influenced by the severity of the patient&#39;s preexisting aortic atherosclerotic... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):265-277. doi: 10.1016/j.jacc.2023.04.053.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> As the bottleneck of endovascular aortic arch repair, early postoperative stroke remains a devastating complication in high-risk patients and a critical concern for the development of optimal endovascular techniques and devices. The incidence of early postoperative stroke varies widely among currently available endovascular techniques and devices, with reported rates ranging from 0.0% to 42.9%, and is significantly influenced by the severity of the patient&#39;s preexisting aortic atherosclerotic burden, air released from the endovascular device, and a variety of factors leading to cerebral perfusion insufficiency. Currently, preidentification of high-risk patients and careful perioperative management appear to play a critical role in reducing stroke incidence. Specific intraoperative prevention methods are still lacking, but embolic protection devices and carbon dioxide or high-volume saline flushing of endovascular devices appear promising. Detailed preoperative stroke risk stratification and screening for optimal endovascular techniques and devices for aortic arch treatment are unmet clinical needs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438011</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.04.053>10.1016/j.jacc.2023.04.053</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438011</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Long Cao</dc:creator><dc:creator> Hongpeng Zhang</dc:creator><dc:creator> Yangyang Ge</dc:creator><dc:creator> Wei Guo</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Avoiding Stroke in Patients Undergoing Endovascular Aortic Arch Repair: JACC Review Topic of the Week</dc:title><dc:identifier> pmid:37438011</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.053</dc:identifier></item><item><title> Consumer Wearable Health and Fitness Technology in Cardiovascular Medicine: JACC State-of-the-Art Review</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230715085802&amp;v=2.17.9.post6+86293ac<description> The use of consumer wearable devices (CWDs) to track health and fitness has rapidly expanded over recent years because of advances in technology. The general population now has the capability to continuously track vital signs, exercise output, and advanced health metrics. Although understanding of basic health metrics may be intuitive (eg, peak heart rate), more complex metrics are derived from proprietary algorithms, differ among device manufacturers, and may not historically be common in... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):245-264. doi: 10.1016/j.jacc.2023.04.054.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The use of consumer wearable devices (CWDs) to track health and fitness has rapidly expanded over recent years because of advances in technology. The general population now has the capability to continuously track vital signs, exercise output, and advanced health metrics. Although understanding of basic health metrics may be intuitive (eg, peak heart rate), more complex metrics are derived from proprietary algorithms, differ among device manufacturers, and may not historically be common in clinical practice (eg, peak V˙O <sub>2</sub> , exercise recovery scores). With the massive expansion of data collected at an individual patient level, careful interpretation is imperative. In this review, we critically analyze common health metrics provided by CWDs, describe common pitfalls in CWD interpretation, provide recommendations for the interpretation of abnormal results, present the utility of CWDs in exercise prescription, examine health disparities and inequities in CWD use and development, and present future directions for research and development.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438010</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.04.054>10.1016/j.jacc.2023.04.054</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438010</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Bradley J Petek</dc:creator><dc:creator> Mostafa A Al-Alusi</dc:creator><dc:creator> Nathaniel Moulson</dc:creator><dc:creator> Aubrey J Grant</dc:creator><dc:creator> Cyril Besson</dc:creator><dc:creator> J Sawalla Guseh</dc:creator><dc:creator> Meagan M Wasfy</dc:creator><dc:creator> Vincent Gremeaux</dc:creator><dc:creator> Timothy W Churchill</dc:creator><dc:creator> Aaron L Baggish</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Consumer Wearable Health and Fitness Technology in Cardiovascular Medicine: JACC State-of-the-Art Review</dc:title><dc:identifier> pmid:37438010</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.054</dc:identifier></item><item><title> (Left) Bundle Up! It&#39;s Getting Cold Out There in the Coronary Sinus</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230715085802&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):242-244. doi: 10.1016/j.jacc.2023.05.019.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438009</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.019>10.1016/j.jacc.2023.05.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438009</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Daniel P Morin</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> (Left) Bundle Up! It&#39;s Getting Cold Out There in the Coronary Sinus</dc:title><dc:identifier> pmid:37438009</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.019</dc:identifier></item><item><title> A Precision Approach to Family Screening in ARVC</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230715085802&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):226-227. doi: 10.1016/j.jacc.2023.05.020.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438008</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.020>10.1016/j.jacc.2023.05.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438008</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Paul A Heidenreich</dc:creator><dc:creator> Francois Haddad</dc:creator><dc:creator> Victoria N Parikh</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> A Precision Approach to Family Screening in ARVC</dc:title><dc:identifier> pmid:37438008</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.020</dc:identifier></item><item><title> Community Volunteer Responder Programs in Cardiac Arrest: The Horse Has Bolted, It&#39;s Time to Optimize</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230715085802&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):211-213. doi: 10.1016/j.jacc.2023.05.018.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438007</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.018>10.1016/j.jacc.2023.05.018</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438007</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Janet E Bray</dc:creator><dc:creator> Christopher M Smith</dc:creator><dc:creator> Ziad Nehme</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Community Volunteer Responder Programs in Cardiac Arrest: The Horse Has Bolted, It&#39;s Time to Optimize</dc:title><dc:identifier> pmid:37438007</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.018</dc:identifier></item><item><title> Dispatch of Volunteer Responders to Out-of-Hospital Cardiac Arrests</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230715085802&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Activation of a volunteer response system in cases of OHCA was associated with a higher chance of bystander CPR, bystander defibrillation, and 30-day survival vs no system activation. A randomized controlled trial is necessary to determine fully the causal effect of volunteer responder systems. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):200-210. doi: 10.1016/j.jacc.2023.05.017.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Systems for dispatch of volunteer responders to collect automated external defibrillators and/or to provide cardiopulmonary resuscitation (CPR) in cases of nearby out-of-hospital cardiac arrest (OHCA) are widely implemented. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: This study aimed to investigate whether the activation of a volunteer responder system to OHCAs was associated with higher rates of bystander CPR, bystander defibrillation, and 30-day survival vs no system activation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This was a retrospective observational analysis within the ESCAPE-NET (European Sudden Cardiac Arrest network: Towards Prevention, Education, New Effective Treatment) collaborative research network. Included were cases of OHCA between 2015 and 2019 from 5 European sites with volunteer responder systems. At all sites, systems were activated by dispatchers at the emergency medical communication center in response to suspected OHCA. Exposed cases (system activation) were compared with nonexposed cases (no system activation). Risk ratios (RRs) were calculated for the outcomes of bystander CPR, bystander defibrillation, and 30-day survival after inverse probability treatment weighting. Missing data were handled using multiple imputation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In total, 9,553 cases were included. In 4,696 cases, the volunteer responder system was activated, and in 4,857 it was not. The pooled RRs were 1.30 (95% CI: 1.15-1.47) for bystander CPR, 1.89 (95% CI: 1.36-2.63) for bystander defibrillation, and 1.22 (95% CI: 1.07-1.39) for 30-day survival. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Activation of a volunteer response system in cases of OHCA was associated with a higher chance of bystander CPR, bystander defibrillation, and 30-day survival vs no system activation. A randomized controlled trial is necessary to determine fully the causal effect of volunteer responder systems.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438006</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.017>10.1016/j.jacc.2023.05.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438006</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Martin Jonsson</dc:creator><dc:creator> Ellinor Berglund</dc:creator><dc:creator> Enrico Baldi</dc:creator><dc:creator> Maria Luce Caputo</dc:creator><dc:creator> Angelo Auricchio</dc:creator><dc:creator> Marieke T Blom</dc:creator><dc:creator> Hanno L Tan</dc:creator><dc:creator> Remy Stieglis</dc:creator><dc:creator> Linn Andelius</dc:creator><dc:creator> Fredrik Folke</dc:creator><dc:creator> Jacob Hollenberg</dc:creator><dc:creator> Leif Svensson</dc:creator><dc:creator> Mattias Ringh</dc:creator><dc:creator> ESCAPE-NET Investigators</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Dispatch of Volunteer Responders to Out-of-Hospital Cardiac Arrests</dc:title><dc:identifier> pmid:37438006</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.017</dc:identifier></item><item><title> Bioresorbable Scaffolds: Is There Still Light at the End of the Tunnel?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37438005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230715085802&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 18;82(3):196-199. doi: 10.1016/j.jacc.2023.05.023.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37438005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230715085802&v=2.17.9.post6+86293ac">37438005</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.023>10.1016/j.jacc.2023.05.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37438005</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Patrick W Serruys</dc:creator><dc:creator> Pruthvi C Revaiah</dc:creator><dc:creator> Yoshinobu Onuma</dc:creator><dc:date> 2023-07-12</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Bioresorbable Scaffolds: Is There Still Light at the End of the Tunnel?</dc:title><dc:identifier> pmid:37438005</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.023</dc:identifier></item></channel></rss>